168 related articles for article (PubMed ID: 35182375)
21. Development of a transformation model to derive general population-based utility: Mapping the pruritus-visual analog scale (VAS) to the EQ-5D utility.
Park SY; Park EJ; Suh HS; Ha D; Lee EK
J Eval Clin Pract; 2017 Aug; 23(4):755-761. PubMed ID: 28194852
[TBL] [Abstract][Full Text] [Related]
22. Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study.
Querfeld C; Nelson WW; Gor D; Pashos CL; Doan QV; Turini M; Angello JT; Geskin LJ
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2781-2795. PubMed ID: 36284059
[TBL] [Abstract][Full Text] [Related]
23. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
24. Systematic review of health state utility values for acute myeloid leukemia.
Forsythe A; Brandt PS; Dolph M; Patel S; Rabe APJ; Tremblay G
Clinicoecon Outcomes Res; 2018; 10():83-92. PubMed ID: 29416365
[TBL] [Abstract][Full Text] [Related]
25. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
26. An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values.
Mukuria C; Rowen D; Harnan S; Rawdin A; Wong R; Ara R; Brazier J
Appl Health Econ Health Policy; 2019 Jun; 17(3):295-313. PubMed ID: 30945127
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Health State Utility Measures in Patients With Head and Neck Cancer.
Noel CW; Lee DJ; Kong Q; Xu W; Simpson C; Brown D; Gilbert RW; Gullane PJ; Irish JC; Huang SH; O'Sullivan B; Goldstein DP; de Almeida JR
JAMA Otolaryngol Head Neck Surg; 2015 Aug; 141(8):696-703. PubMed ID: 26204439
[TBL] [Abstract][Full Text] [Related]
28. Mapping algorithms from QLQ-C30 to EQ-5D utilities: no firm ground to stand on yet.
Crott R
Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):569-76. PubMed ID: 24910212
[TBL] [Abstract][Full Text] [Related]
29. The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression.
Wang Y; Gavan SP; Steinke D; Cheung KL; Chen LC
Health Qual Life Outcomes; 2022 Dec; 20(1):169. PubMed ID: 36564800
[TBL] [Abstract][Full Text] [Related]
30. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
31. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
32. Mapping the University of Washington Quality of life questionnaire onto EQ-5D and HUI-3 indices in patients with head and neck cancer.
Stephens RF; Noel CW; Su JS; Xu W; Krahn M; Monteiro E; Goldstein DP; Giuliani M; Hansen AR; de Almeida JR
Head Neck; 2020 Mar; 42(3):513-521. PubMed ID: 31762112
[TBL] [Abstract][Full Text] [Related]
33. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides.
Chong BF; Wilson AJ; Gibson HM; Hafner MS; Luo Y; Hedgcock CJ; Wong HK
Clin Cancer Res; 2008 Feb; 14(3):646-53. PubMed ID: 18245523
[TBL] [Abstract][Full Text] [Related]
34. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
35. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
Doble B; Lorgelly P
Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients.
Lefrançois P; Xie P; Wang L; Tetzlaff MT; Moreau L; Watters AK; Netchiporouk E; Provost N; Gilbert M; Ni X; Sasseville D; Wheeler DA; Duvic M; Litvinov IV
Oncoimmunology; 2018; 7(8):e1467856. PubMed ID: 30221071
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
[TBL] [Abstract][Full Text] [Related]
38. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement.
Dakin H; Abel L; Burns R; Yang Y
Health Qual Life Outcomes; 2018 Feb; 16(1):31. PubMed ID: 29433510
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
